Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16387389 | 0.89 | CYP3A4 (0.49) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL16246331 | 0.86 | CYP3A4 (0.48) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL16387388 | 0.85 | CYP3A4 (0.51) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| Acrylic Acid SCHEMBL28057784 | 0.81 | TSHR (0.43) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL31644815 | 0.77 | CYP3A4 (0.53) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL3741046 | 0.77 | TSHR (0.48) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL29335199 | 0.76 | CYP3A4 (0.50) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL31260368 | 0.75 | CYP3A4 (0.51) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL16914479 | 0.74 | CYP3A4 (0.48) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL21111948 | 0.74 | ALDH1A1 (0.50) | CYP3A4TSHRTDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| EP-2994463-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2994463-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016193812-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | ABBVIE S.A.R.L. (LU) | 2016-12-08 | — | — | WO | disclosed |
| US-20160355480-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-12-08 | — | — | US | disclosed |
| US-20160355480-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-12-08 | — | — | US | disclosed |
| US-20160355480-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-12-08 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | disclosed |
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | disclosed |
| EP-2994463-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | Galapagos NV (BE) | 2016-03-16 | — | — | EP | disclosed |
| US-20150005275-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. | GALAPAGOS NV (BE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005275-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. | GALAPAGOS NV (BE) | 2015-01-01 | — | — | US | disclosed |
| WO-2014180562-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014180562-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC3, ABCC5 | CYP3A4 1865/4885TSHR 3056/4885TDP1 4753/4885 |
| US-20160355480-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | CFTR, P2RY1, XDH | CYP3A4 206/4885TSHR 1726/4885TDP1 3360/4885 |
| US-20150005275-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. | CFTR, ABCC3, ABCC5 | CYP3A4 1524/4885TSHR 2683/4885TDP1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.